integrated health
Lilly to acquire Merida Biosciences in deal worth up to $2.875bn
The acquisition is to advance treatments for serious autoimmune and allergic diseases
Ipsen to acquire Memo Therapeutics in deal worth more than €700m
The deal expands the company’s rare disease portfolio
Vertex to acquire Crinetics in deal worth around $10bn
The deal includes an approved treatment for acromegaly and other pipeline candidates
Novartis to acquire Myricx Bio in deal worth $1.5bn
Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates
Klick Health acquires Oxford PharmaGenesis
The move expands Klick’s scientific expertise in oncology and rare diseases
Zymeworks to acquire Theravance Biopharma in deal worth $929m
The acquisition will give the company access to a treatment for COPD
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma
Biogen to acquire RayThera in $1bn deal
The acquisition will expand the company’s immunology pipeline
Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn
The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease
Lilly to acquire Curevo in deal worth $1.5bn
The acquisition will help build Lilly’s infectious disease portfolio
Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn
Catalyst Pharmaceuticals is focused on novel medicines for rare diseases
Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn
The acquisition will help Lilly to expand its capabilities in cell and gene therapy